COO of Invitae Corp (30-Year Financial, Insider Trades) E Lee Bendekgey (insider trades) sold 21,265 shares of NVTA on 08/19/2019 at an average price of $25.29 a share. The total sale was $537,792.
Invitae Corp is a genetic information company engaged in genetic diagnostics for hereditary disorders. It provides testing for multiple genes including hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. Invitae Corp has a market cap of $2.52 billion; its shares were traded at around $26.45 with and P/S ratio of 12.03. GuruFocus has detected 2 severe warning signs with Invitae Corp. .
CEO Recent Trades:
- President & CEO Sean E George sold 16,358 shares of NVTA stock on 08/19/2019 at the average price of $25.29. The price of the stock has increased by 4.59% since.
CFO Recent Trades:
- CFO Shelly D Guyer sold 24,447 shares of NVTA stock on 08/19/2019 at the average price of $25.38. The price of the stock has increased by 4.22% since.
Directors and Officers Recent Trades:
- COO E Lee Bendekgey sold 21,265 shares of NVTA stock on 08/19/2019 at the average price of $25.29. The price of the stock has increased by 4.59% since.
- Chief Medical Officer Robert L Nussbaum sold 20,447 shares of NVTA stock on 08/19/2019 at the average price of $25.29. The price of the stock has increased by 4.59% since.
- Chief Commercial Officer Katherine Stueland sold 22,900 shares of NVTA stock on 08/19/2019 at the average price of $25.29. The price of the stock has increased by 4.59% since.
- General Counsel Thomas Brida sold 13,663 shares of NVTA stock on 08/19/2019 at the average price of $25.29. The price of the stock has increased by 4.59% since.
- Chief Commercial Officer Katherine Stueland sold 3,789 shares of NVTA stock on 08/16/2019 at the average price of $24.98. The price of the stock has increased by 5.88% since.
For the complete insider trading history of NVTA, click here
.
